Atlas Trials

Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors

Clinical trial NCT01326702 · COMPLETED

Trial details

NCT number
NCT01326702
Sponsor
National Cancer Institute (NCI)
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Adult B Acute Lymphoblastic LeukemiaAdult Nasal Type Extranodal NK/T-Cell LymphomaAdult Solid NeoplasmAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell LymphomaChronic Lymphocytic LeukemiaCutaneous B-Cell Non-Hodgkin LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueHepatosplenic T-Cell LymphomaIntraocular LymphomaLymphomatous Involvement of Non-Cutaneous Extranodal SiteMature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Start date
2011-07-01
Primary completion
2015-04-01
Enrollment
43

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.